FY2018 Earnings Estimate for Lipocine Inc. Issued By Roth Capital (LPCN)
Lipocine Inc. (NASDAQ:LPCN) – Roth Capital lifted their FY2018 EPS estimates for shares of Lipocine in a report released on Monday. Roth Capital analyst M. Higgins now forecasts that the firm will earn $2.52 per share for the year, up from their previous forecast of $2.50.
Lipocine (NASDAQ:LPCN) last released its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05.
A number of other equities analysts have also recently issued reports on LPCN. HC Wainwright assumed coverage on Lipocine in a report on Friday, October 7th. They set a “buy” rating and a $25.00 target price on the stock. Canaccord Genuity restated a “buy” rating and set a $15.00 target price (up previously from $6.00) on shares of Lipocine in a report on Tuesday, October 11th.
Lipocine (NASDAQ:LPCN) traded up 0.56% during trading on Tuesday, reaching $3.62. The company had a trading volume of 324,632 shares. The company has a 50 day moving average price of $3.95 and a 200 day moving average price of $6.18. Lipocine has a 52-week low of $2.51 and a 52-week high of $14.80. The company’s market capitalization is $66.09 million.
A number of institutional investors have recently modified their holdings of LPCN. California State Teachers Retirement System bought a new position in shares of Lipocine during the second quarter worth about $106,000. Landscape Capital Management L.L.C. acquired a new position in Lipocine during the first quarter valued at $385,000. BlackRock Investment Management LLC boosted its position in Lipocine by 2,370.7% in the second quarter. BlackRock Investment Management LLC now owns 62,707 shares of the specialty pharmaceutical company’s stock valued at $191,000 after buying an additional 60,169 shares during the period. DRW Securities LLC acquired a new position in Lipocine during the second quarter valued at $443,000. Finally, State Street Corp boosted its position in Lipocine by 1,408.9% in the second quarter. State Street Corp now owns 200,679 shares of the specialty pharmaceutical company’s stock valued at $609,000 after buying an additional 187,379 shares during the period. Hedge funds and other institutional investors own 47.22% of the company’s stock.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Stock Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related stocks with our FREE daily email newsletter.